Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.
We speak to Dr. Ruth Kroschewski about new research that details the existence of an 'exclusome', a cytoplasmic container that appears to explain where extra-chromosomal DNA goes once it is in a cell.
Researchers have revealed the modulatory effect of the anti-inflammatory metabolite itaconate on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.
The biological function of the C-reactive protein, CRP, has long been unidentified. Investigators at LiU have discovered that this protein has a useful function in the inflammatory disease systemic lupus erythematosus or SLE.
The biological function of the C-reactive protein, CRP, has long been unknown. Researchers at Linköping University in Sweden now show that this protein has a beneficial function in systemic lupus erythematosus, SLE, an inflammatory disease.
Researchers from Nagoya University’s Graduate School of Medicine in Japan have uncovered how microRNA (miRNA) affects inflammation in mice with lupus. They discovered two downregulated miRNAs in the disease along with a rare circumstance where several miRNAs control the same set of genes.
Institut Pasteur, Université Paris Cité, the CNRS, and the Collège de France researchers have employed paleogenomics to trace 10,000 years of human immune system evolution. They examined the genomes of over 2,800 individuals who lived in Europe over the past 10 millennia.
CAR T cells, or engineered immune cells, have demonstrated to the world the potential of customized immunotherapies to treat blood cancers. Researchers have just released highly encouraging preliminary data for CAR T therapy in a small group of lupus patients.
Some genetic polymorphisms might expose individuals to the risk of autoimmune diseases while also protecting them against the effects of viral infection.
There is still a large unmet medical need for the treatment of ulcerative colitis, despite recent improvements in the understanding of the pathogenic mechanisms of ulcerative colitis.
A first-of-its-kind genetic database for autoinflammatory and autoimmune disorders has been created by Japanese researchers.
For all their importance as a breakthrough treatment, the cancer immunotherapies known as checkpoint inhibitors still only benefit a small minority of patients, perhaps 15 percent across different types of cancer. Moreover, doctors cannot accurately predict which of their patients will respond.
Autoimmune diseases, in which the body's own immune system attacks healthy tissue, can be life-threatening and can impact all organs.
According to a research team, headed by Decio L. Eizirik, MD, PhD, a Scientific Director from the Indiana Biosciences Research Institute Diabetes Center, new treatments for autoimmune disorders can be identified by studying both target tissues and the immune system together.
Scientists from Emory Health Sciences have been observing an intense stimulation of immune cells in severe cases of COVID-19 disease. This activation of immune cells is similar to acute flares of systemic lupus erythematosus (SLE)—an autoimmune disease.
A team of researchers from Children's Hospital of Philadelphia used a new method of pinpointing potential disease-causing changes in the genome to identify two new potential therapeutic targets for lupus, while also paving the way for more accurately identifying disease-causing variations in other autoimmune disorders.
The human immune system is expected to guard people against the invasion of external microbes, but at times, it possibly leads to autoimmune disorders.
How cells recognize pathogens and alert the immune system swiftly is a fundamental process of high importance for the survival of any species, including humans.
Working alongside colleagues in Mainz, Bern, Hannover and Bonn, researchers from Charité - Universitätsmedizin Berlin, the Berlin Institute of Health and the German Rheumatism Research Center Berlin were able to show how the microbiome helps to render the immune system capable of responding to pathogens.
Chandra Mohan, a Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering at the University of Houston, and his colleagues have identified a race-specific variance in the urinary biomarker proteins of lupus nephritis (LN) in patients.